Abstract:Drug repositioning, an important method of drug development, is utilized to discover investigational drugs beyond the originally approved indications, expand the application scope of drugs, and reduce the cost of drug development. With the emergence of increasingly drug-disease-related biological networks, the challenge still remains to effectively fuse biological entity data and accurately achieve drug-disease repositioning. This paper proposes a new drug repositioning method named EMPHCN based on enhanced message passing and hypergraph convolutional networks (HGCN). It firstly constructs the homogeneous multi-view information with multiple drug similarity features and then extracts the intra-domain embedding of drugs through the combination of HGCN and channel attention mechanism. Secondly, inter-domain information of known drug-disease associations is extracted by graph convolutional networks combining node and edge embedding (NEEGCN), and a heterogeneous network composed of drugs, proteins and diseases is built as an important auxiliary to enhance the inter-domain message passing of drugs and diseases. Besides, the intra-domain embedding of diseases is also extracted through HGCN. Ultimately, intra-domain and inter-domain embeddings of drugs and diseases are integrated as the final embedding for calculating the drug-disease correlation matrix. Through 10-fold cross-validation on some benchmark datasets, we find that the AUPR of EMPHCN reaches 0.593 (T1) and 0.526 (T2), respectively, and the AUC achieves 0.887 (T1) and 0.961 (T2) respectively, which shows that EMPHCN has an advantage over other state-of-the-art prediction methods. Concerning the new disease association prediction, the AUC of EMPHCN through the five-fold cross-validation reaches 0.806 (T1) and 0.845 (T2), which are 4.3% (T1) and 4.0% (T2) higher than the second best existing methods, respectively. In the case study, EMPHCN also achieves satisfactory results in real drug repositioning for breast carcinoma and Parkinson's disease.

Drug Repositioning by Multi-Aspect Heterogeneous Graph Contrastive Learning and Positive-Fusion Negative Sampling Strategy

Drug repositioning based on the heterogeneous information fusion graph convolutional network

Drug Repositioning by Collaborative Learning Based on Graph Convolutional Inductive Network

Drug Repositioning Via Multi-view Representation Learning with Heterogeneous Graph Neural Network

Enhancing Drug Repositioning through Contrastive Learning and Denoised Negative Sampling.

Hierarchical Negative Sampling Based Graph Contrastive Learning Approach for Drug-Disease Association Prediction

DRGCL: Drug Repositioning Via Semantic-enriched Graph Contrastive Learning.

Drug repositioning with adaptive graph convolutional networks

Drug repositioning based on weighted local information augmented graph neural network

A Novel Graph Representation Learning Model for Drug Repositioning Using Graph Transition Probability Matrix over Heterogenous Information Networks.

An Effective Multi-Task Learning Framework for Drug Repurposing Based on Graph Representation Learning.

A geometric deep learning framework for drug repositioning over heterogeneous information networks

Drug Repositioning Based on Deep Sparse Autoencoder and Drug-Disease Similarity

Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks

Semantic-enhanced Graph Contrastive Learning with Adaptive Denoising for Drug Repositioning.

Regulation-aware graph learning for drug repositioning over heterogeneous biological network

Fusing Higher and Lower-Order Biological Information for Drug Repositioning Via Graph Representation Learning

Knowledge Graph Convolutional Network with Heuristic Search for Drug Repositioning

Attention Transfer in Heterogeneous Networks Fusion for Drug Repositioning

Heterogeneous graph inference with matrix completion for computational drug repositioning

Drug Repositioning Based on Multi-View Learning with Matrix Completion